Concepts (321)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 4 | 2020 | 96 | 2.200 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2019 | 14 | 1.720 |
Why?
|
| Neoplasms | 12 | 2024 | 763 | 1.670 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2019 | 10 | 1.520 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 245 | 1.090 |
Why?
|
| Models, Statistical | 4 | 2018 | 187 | 0.960 |
Why?
|
| Prediabetic State | 2 | 2023 | 76 | 0.880 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2015 | 43 | 0.870 |
Why?
|
| Humans | 62 | 2024 | 32271 | 0.850 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 101 | 0.840 |
Why?
|
| Orthopedic Nursing | 2 | 2020 | 4 | 0.800 |
Why?
|
| Preoperative Care | 2 | 2020 | 125 | 0.750 |
Why?
|
| Perception | 2 | 2020 | 99 | 0.730 |
Why?
|
| Treatment Outcome | 9 | 2024 | 3408 | 0.710 |
Why?
|
| Cardiovascular Diseases | 3 | 2024 | 1159 | 0.670 |
Why?
|
| Research Design | 5 | 2023 | 316 | 0.670 |
Why?
|
| Patient Discharge | 2 | 2019 | 204 | 0.660 |
Why?
|
| Nurses | 1 | 2020 | 14 | 0.620 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 1437 | 0.610 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 24 | 0.590 |
Why?
|
| Tretinoin | 1 | 2019 | 33 | 0.590 |
Why?
|
| Statistics as Topic | 1 | 2018 | 99 | 0.540 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 245 | 0.520 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 422 | 0.520 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 180 | 0.510 |
Why?
|
| Adult | 23 | 2024 | 9260 | 0.510 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 545 | 0.510 |
Why?
|
| Medulloblastoma | 1 | 2017 | 8 | 0.510 |
Why?
|
| Cerebellar Neoplasms | 1 | 2017 | 11 | 0.510 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 595 | 0.510 |
Why?
|
| Female | 33 | 2024 | 19943 | 0.500 |
Why?
|
| Maximum Tolerated Dose | 3 | 2018 | 62 | 0.490 |
Why?
|
| Vaginal Smears | 2 | 2014 | 9 | 0.480 |
Why?
|
| Medical Records | 2 | 2013 | 75 | 0.470 |
Why?
|
| Social Work | 2 | 2024 | 8 | 0.460 |
Why?
|
| Middle Aged | 24 | 2024 | 11838 | 0.440 |
Why?
|
| Male | 29 | 2024 | 19437 | 0.420 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2018 | 105 | 0.400 |
Why?
|
| Head and Neck Neoplasms | 3 | 2024 | 137 | 0.400 |
Why?
|
| Young Adult | 10 | 2018 | 2651 | 0.390 |
Why?
|
| Mass Screening | 2 | 2022 | 256 | 0.380 |
Why?
|
| Aging | 4 | 2018 | 942 | 0.380 |
Why?
|
| Kentucky | 5 | 2015 | 15 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 158 | 0.360 |
Why?
|
| Computer Simulation | 4 | 2018 | 251 | 0.360 |
Why?
|
| Lip | 3 | 2017 | 7 | 0.360 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 220 | 0.340 |
Why?
|
| Postural Balance | 2 | 2018 | 142 | 0.330 |
Why?
|
| Patient Compliance | 1 | 2012 | 206 | 0.330 |
Why?
|
| Telemedicine | 2 | 2023 | 122 | 0.330 |
Why?
|
| Quality of Life | 6 | 2024 | 969 | 0.320 |
Why?
|
| Aged | 17 | 2024 | 10249 | 0.320 |
Why?
|
| Food Supply | 2 | 2011 | 64 | 0.310 |
Why?
|
| Smoking Cessation | 2 | 2023 | 211 | 0.310 |
Why?
|
| Adolescent | 9 | 2018 | 3516 | 0.300 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 764 | 0.280 |
Why?
|
| Lymphocyte Depletion | 1 | 2018 | 18 | 0.270 |
Why?
|
| Voice Quality | 2 | 2018 | 6 | 0.270 |
Why?
|
| Kidney Failure, Chronic | 2 | 2022 | 534 | 0.270 |
Why?
|
| Laryngeal Neoplasms | 2 | 2017 | 16 | 0.260 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 140 | 0.250 |
Why?
|
| Guideline Adherence | 2 | 2014 | 109 | 0.250 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 388 | 0.250 |
Why?
|
| United States | 8 | 2024 | 4069 | 0.240 |
Why?
|
| Vibration | 2 | 2015 | 10 | 0.240 |
Why?
|
| Doxorubicin | 2 | 2017 | 75 | 0.240 |
Why?
|
| Obesity | 2 | 2023 | 1111 | 0.240 |
Why?
|
| Appalachian Region | 3 | 2015 | 23 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 156 | 0.210 |
Why?
|
| Touch Perception | 1 | 2014 | 2 | 0.210 |
Why?
|
| Communications Media | 1 | 2024 | 4 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Xerostomia | 1 | 2024 | 28 | 0.210 |
Why?
|
| Acupuncture Therapy | 1 | 2024 | 18 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 2238 | 0.210 |
Why?
|
| Referral and Consultation | 2 | 2017 | 137 | 0.210 |
Why?
|
| Aromatase Inhibitors | 1 | 2013 | 8 | 0.200 |
Why?
|
| Postoperative Complications | 2 | 2021 | 818 | 0.200 |
Why?
|
| Papillomavirus Infections | 2 | 2015 | 70 | 0.200 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.200 |
Why?
|
| Nurse Practitioners | 1 | 2024 | 12 | 0.200 |
Why?
|
| Sirolimus | 1 | 2013 | 34 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 716 | 0.200 |
Why?
|
| Needs Assessment | 1 | 2024 | 78 | 0.200 |
Why?
|
| Gamma Rays | 1 | 2013 | 25 | 0.200 |
Why?
|
| Tumor Burden | 1 | 2013 | 62 | 0.200 |
Why?
|
| Treatment Failure | 1 | 2013 | 164 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Risk Factors | 4 | 2024 | 3933 | 0.200 |
Why?
|
| Radiation Injuries | 1 | 2024 | 85 | 0.200 |
Why?
|
| Pilot Projects | 5 | 2023 | 554 | 0.200 |
Why?
|
| Radiation Dosage | 1 | 2013 | 90 | 0.200 |
Why?
|
| Estradiol | 1 | 2013 | 139 | 0.190 |
Why?
|
| Tobacco Use Cessation | 1 | 2023 | 22 | 0.190 |
Why?
|
| Medical Oncology | 4 | 2024 | 90 | 0.190 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1480 | 0.190 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 49 | 0.190 |
Why?
|
| Caregivers | 1 | 2024 | 114 | 0.190 |
Why?
|
| Social Support | 2 | 2024 | 181 | 0.180 |
Why?
|
| Age Factors | 4 | 2018 | 1178 | 0.180 |
Why?
|
| Nutritional Status | 1 | 2013 | 73 | 0.180 |
Why?
|
| Music Therapy | 1 | 2022 | 6 | 0.180 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 87 | 0.180 |
Why?
|
| Vitamin D | 1 | 2013 | 186 | 0.170 |
Why?
|
| Overweight | 1 | 2023 | 252 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Electric Stimulation Therapy | 1 | 2021 | 19 | 0.170 |
Why?
|
| Muscle Weakness | 1 | 2021 | 34 | 0.170 |
Why?
|
| Quadriceps Muscle | 1 | 2021 | 29 | 0.160 |
Why?
|
| Knee Injuries | 1 | 2021 | 36 | 0.160 |
Why?
|
| Infant | 3 | 2018 | 1010 | 0.160 |
Why?
|
| Child | 4 | 2023 | 2431 | 0.160 |
Why?
|
| Geography | 1 | 2010 | 30 | 0.160 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 22 | 0.160 |
Why?
|
| Radiosurgery | 1 | 2013 | 355 | 0.160 |
Why?
|
| Child, Preschool | 3 | 2018 | 1233 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 195 | 0.150 |
Why?
|
| Qualitative Research | 1 | 2020 | 180 | 0.150 |
Why?
|
| Algorithms | 2 | 2018 | 536 | 0.150 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 489 | 0.150 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 117 | 0.150 |
Why?
|
| Behavior Therapy | 1 | 2019 | 103 | 0.140 |
Why?
|
| Brain | 2 | 2017 | 966 | 0.140 |
Why?
|
| Sample Size | 1 | 2018 | 38 | 0.140 |
Why?
|
| Vaccination | 1 | 2010 | 156 | 0.140 |
Why?
|
| Muscle Fatigue | 1 | 2018 | 13 | 0.140 |
Why?
|
| Rural Population | 2 | 2015 | 216 | 0.140 |
Why?
|
| Voice Disorders | 1 | 2018 | 5 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2017 | 1839 | 0.140 |
Why?
|
| Infant, Newborn | 2 | 2018 | 666 | 0.140 |
Why?
|
| Shoulder | 1 | 2018 | 50 | 0.140 |
Why?
|
| Brain Concussion | 1 | 2018 | 41 | 0.140 |
Why?
|
| Survivors | 3 | 2024 | 174 | 0.140 |
Why?
|
| Sports Medicine | 1 | 2018 | 28 | 0.140 |
Why?
|
| Probability | 1 | 2018 | 155 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 637 | 0.130 |
Why?
|
| Cluster Analysis | 2 | 2012 | 120 | 0.130 |
Why?
|
| Voice Training | 1 | 2017 | 1 | 0.130 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 194 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2019 | 135 | 0.130 |
Why?
|
| Laryngectomy | 1 | 2017 | 3 | 0.130 |
Why?
|
| Adipose Tissue, Brown | 1 | 2017 | 8 | 0.130 |
Why?
|
| Propranolol | 1 | 2017 | 17 | 0.130 |
Why?
|
| Length of Stay | 1 | 2019 | 321 | 0.130 |
Why?
|
| Vocal Cords | 1 | 2017 | 10 | 0.130 |
Why?
|
| Visual Perception | 1 | 2018 | 121 | 0.130 |
Why?
|
| Otolaryngology | 1 | 2017 | 15 | 0.130 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 327 | 0.130 |
Why?
|
| Myocytes, Cardiac | 1 | 2017 | 90 | 0.130 |
Why?
|
| Muscle Contraction | 1 | 2018 | 175 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 52 | 0.130 |
Why?
|
| Athletic Injuries | 1 | 2018 | 82 | 0.130 |
Why?
|
| Face | 1 | 2017 | 29 | 0.130 |
Why?
|
| Tracheostomy | 1 | 2017 | 28 | 0.130 |
Why?
|
| Retrospective Studies | 6 | 2018 | 3609 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 55 | 0.130 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 167 | 0.130 |
Why?
|
| Demography | 1 | 2017 | 101 | 0.130 |
Why?
|
| Sensation | 1 | 2017 | 60 | 0.120 |
Why?
|
| Salvage Therapy | 1 | 2017 | 135 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 39 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2017 | 114 | 0.120 |
Why?
|
| Glioblastoma | 1 | 2018 | 159 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 170 | 0.120 |
Why?
|
| Stroke | 1 | 2022 | 691 | 0.120 |
Why?
|
| Muscle, Skeletal | 2 | 2017 | 520 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 108 | 0.120 |
Why?
|
| Auditory Threshold | 1 | 2015 | 2 | 0.110 |
Why?
|
| Mesna | 1 | 2015 | 3 | 0.110 |
Why?
|
| Protective Agents | 1 | 2015 | 4 | 0.110 |
Why?
|
| Genes, p16 | 1 | 2015 | 1 | 0.110 |
Why?
|
| Survival Rate | 3 | 2018 | 892 | 0.110 |
Why?
|
| SEER Program | 1 | 2015 | 38 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2015 | 43 | 0.110 |
Why?
|
| Carboplatin | 1 | 2015 | 42 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 772 | 0.110 |
Why?
|
| Paclitaxel | 1 | 2015 | 57 | 0.110 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 23 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 49 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2015 | 56 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 39 | 0.110 |
Why?
|
| Meningioma | 1 | 2015 | 59 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 324 | 0.100 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 43 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 215 | 0.100 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 3 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2024 | 21 | 0.100 |
Why?
|
| Directive Counseling | 1 | 2013 | 19 | 0.100 |
Why?
|
| Colonoscopy | 1 | 2013 | 45 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 3893 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2013 | 171 | 0.100 |
Why?
|
| Hospitals, Public | 1 | 2012 | 4 | 0.100 |
Why?
|
| Community-Based Participatory Research | 1 | 2014 | 114 | 0.090 |
Why?
|
| Time Factors | 1 | 2018 | 2203 | 0.090 |
Why?
|
| Rural Health Services | 1 | 2012 | 23 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2014 | 128 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 73 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 316 | 0.090 |
Why?
|
| Lung | 2 | 2023 | 263 | 0.080 |
Why?
|
| Restaurants | 2 | 2011 | 9 | 0.080 |
Why?
|
| Radiotherapy | 2 | 2024 | 92 | 0.080 |
Why?
|
| Single-Blind Method | 2 | 2022 | 192 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2018 | 854 | 0.080 |
Why?
|
| Hypertension | 1 | 2017 | 980 | 0.080 |
Why?
|
| Renal Dialysis | 2 | 2022 | 275 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 854 | 0.080 |
Why?
|
| Depression | 2 | 2023 | 427 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 442 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 322 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2024 | 864 | 0.060 |
Why?
|
| Comorbidity | 1 | 2018 | 563 | 0.060 |
Why?
|
| Population Surveillance | 2 | 2018 | 120 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2017 | 274 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2018 | 476 | 0.060 |
Why?
|
| Cancer Care Facilities | 1 | 2024 | 10 | 0.050 |
Why?
|
| Sensory Thresholds | 1 | 2014 | 28 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 880 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 40 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 83 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 104 | 0.050 |
Why?
|
| Glucose | 1 | 2024 | 160 | 0.050 |
Why?
|
| Communication | 1 | 2024 | 129 | 0.050 |
Why?
|
| Dyspnea | 1 | 2023 | 32 | 0.050 |
Why?
|
| Micronutrients | 1 | 2013 | 20 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2024 | 148 | 0.050 |
Why?
|
| Cholesterol | 1 | 2024 | 262 | 0.050 |
Why?
|
| Walking | 1 | 2023 | 199 | 0.050 |
Why?
|
| Urban Population | 1 | 2013 | 91 | 0.050 |
Why?
|
| Medicare | 1 | 2024 | 218 | 0.050 |
Why?
|
| Patient Participation | 1 | 2023 | 90 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1300 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 248 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 312 | 0.040 |
Why?
|
| Urea | 1 | 2021 | 38 | 0.040 |
Why?
|
| Health Status | 1 | 2024 | 356 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 309 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2017 | 2315 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2013 | 455 | 0.040 |
Why?
|
| Affect | 1 | 2022 | 75 | 0.040 |
Why?
|
| Anxiety | 1 | 2023 | 195 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2023 | 249 | 0.040 |
Why?
|
| Food Industry | 1 | 2011 | 7 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 24 | 0.040 |
Why?
|
| South Carolina | 1 | 2011 | 29 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2012 | 139 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 373 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 302 | 0.040 |
Why?
|
| Logistic Models | 1 | 2013 | 743 | 0.040 |
Why?
|
| Population Density | 1 | 2010 | 9 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2010 | 39 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2021 | 135 | 0.040 |
Why?
|
| Prevalence | 1 | 2013 | 955 | 0.040 |
Why?
|
| Data Collection | 1 | 2010 | 171 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2013 | 863 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 410 | 0.040 |
Why?
|
| Proprioception | 1 | 2018 | 6 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2024 | 1423 | 0.030 |
Why?
|
| Torque | 1 | 2018 | 21 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 54 | 0.030 |
Why?
|
| Smoking | 1 | 2022 | 505 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 72 | 0.030 |
Why?
|
| Athletes | 1 | 2018 | 62 | 0.030 |
Why?
|
| Aldehydes | 1 | 2017 | 6 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2017 | 29 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 41 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 395 | 0.030 |
Why?
|
| Proteome | 1 | 2017 | 41 | 0.030 |
Why?
|
| Stroboscopy | 1 | 2017 | 1 | 0.030 |
Why?
|
| Speech Disorders | 1 | 2017 | 6 | 0.030 |
Why?
|
| Speech | 1 | 2017 | 8 | 0.030 |
Why?
|
| Speech Acoustics | 1 | 2017 | 4 | 0.030 |
Why?
|
| Pulmonary Ventilation | 1 | 2017 | 12 | 0.030 |
Why?
|
| Larynx | 1 | 2017 | 17 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 250 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 129 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 168 | 0.030 |
Why?
|
| Proteomics | 1 | 2017 | 97 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 180 | 0.030 |
Why?
|
| Fever | 1 | 2017 | 59 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 367 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 551 | 0.030 |
Why?
|
| Auditory Perception | 1 | 2017 | 80 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 72 | 0.030 |
Why?
|
| Shoulder Joint | 1 | 2018 | 138 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 756 | 0.030 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 197 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 759 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2015 | 5 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2015 | 83 | 0.030 |
Why?
|
| Solubility | 1 | 2015 | 39 | 0.030 |
Why?
|
| Heart Rate | 1 | 2017 | 364 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 86 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 792 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 25 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 92 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 95 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 28 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 83 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 484 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 23 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 2015 | 25 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2015 | 39 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 492 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 157 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 249 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 286 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 315 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 1081 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 294 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 458 | 0.020 |
Why?
|
| Women's Health | 1 | 2015 | 230 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 1529 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 242 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2015 | 349 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2571 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1242 | 0.020 |
Why?
|
| African Americans | 1 | 2015 | 1335 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 8196 | 0.010 |
Why?
|